NASDAQ:CGTX Cognition Therapeutics Q1 2025 Earnings Report $0.96 +0.01 (+0.59%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.01 (+0.83%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cognition Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.12Beat/MissMissed by -$0.02One Year Ago EPSN/ACognition Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACognition Therapeutics Announcement DetailsQuarterQ1 2025Date5/6/2025TimeBefore Market OpensConference Call DateWednesday, May 7, 2025Conference Call Time7:30AM ETUpcoming EarningsCognition Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cognition Therapeutics Earnings HeadlinesCognition Set For Type C FDA Meeting In Oct '26 On Planned Phase 3 For Dementia Drug ZervimesineSeptember 29 at 10:24 PM | rttnews.comCognition Therapeutics Schedules FDA Type C Meeting to Discuss Phase 3 Trial Endpoint for Zervimesine in Dementia with Lewy BodiesSeptember 29 at 7:51 AM | quiverquant.comQMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 30 at 1:00 AM | TradeSmith (Ad)Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLBSeptember 29 at 7:30 AM | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $3.33 Consensus Target Price from AnalystsSeptember 23, 2026 | americanbankingnews.comCognition Therapeutics to Present Zervimesine Development Progress at H.C. Wainwright Global Investment ConferenceSeptember 8, 2026 | quiverquant.comQSee More Cognition Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email. Email Address About Cognition TherapeuticsCognition Therapeutics (NASDAQ:CGTX) is a clinical-stage biotechnology company focused on developing medicines for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as SIGMAR2, a protein believed to play a role in the cellular processes associated with cognitive decline and neurodegeneration. Cognition Therapeutics’ lead product candidate is CT1812, an orally administered, brain-penetrant small molecule designed to modulate SIGMAR2. The investigational therapy is being evaluated for Alzheimer’s disease and other forms of dementia, including dementia with Lewy bodies. CT1812 has not been approved for commercial use, and its safety and effectiveness remain under evaluation in clinical trials. Founded in 2007, Cognition Therapeutics conducts its research and clinical development activities primarily in the United States. The company is headquartered in Purchase, New York, and is led by President and Chief Executive Officer Lisa K. Miller.View Cognition Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
